Please login to the form below

Seattle Genetics

This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.

Immunomedics craters after FDA rejects breast cancer ADC

The drug was the subject of an investor revolt when the biotech’s former management tried to license it to Seattle Genetics in 2017, which ultimately claimed the scalps of Immunomedics’

Latest news

AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
Bluebird and Celgene BCMA CAR-T kicks off ASCO

to license it to Seattle Genetics last year - while other breast cancer ADCs on the agenda at ASCO include Daiichi is developing trastuzumab deruxtecan and Takeda/Mersana’s XMT-1522.
Seattle Genetics claims key US approval for Adcetris

Seattle Genetics has won FDA approval for Adcetris as a first-line treatment for advanced Hodgkin’s lymphoma, which it believes could help unlock blockbuster sales for the drug in the ... Seattle has since turned its attention to its own TNBC candidate
Takeda bags EU approval for Adcetris in lymphoma

Originally developed by Seattle Genetics, Adcetris has been on the market for just over six years and has seen sales grow steadily to around $600m last year, driven by a stream ... There are more new indications on the way, and Takeda and Seattle
Seattle Genetics' Adcetris earns FDA priority review status

Seattle Genetics’ Adcetris has received a boost after the US Food and Drug Administration’s (FDA) granted the lymphoma drug priority review status. ... Clay Siegall, president and chief executive officer of Seattle Genetics, said: “We recently

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Winding back to last February (DW Issue 80), Immunomedics announced a licensing agreement with
Deal Watch March 2017

In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
Deal Watch February 2017

Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
Pharma deals in June 2015

NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
Deal Watch table for September 2014

244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

BMS appoints new commercial leader, Davies joins Eisai and more

Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.
Douglas Williams named president and CEO of Codiak

These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
VentiRx appoints James Kyle Bryan as chief medical officer

Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Client Services Director- Flexible Working: Negotiable

Senior Medical Writer: Competitive salary plus benefits

Events Executive: DOE

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Manager – Healthcare advertising: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...